Key result
Combination of aspirin and a thromboxane synthase inhibitor in healthy volunteers increased ex vivo thromboxane inhibition (98% vs 94%; P<0.05) and in vivo synthesis inhibition (58%; P<0.01).
Why the study?
Does the combination of aspirin and a thromboxane synthase inhibitor improve the inhibition of thromboxane synthesis in vivo compared to either drug alone in healthy volunteers?
Population
18 healthy volunteers (12 in the main study, 6 in the low-dose aspirin study)
Comparison
Aspirin 120 mg, thromboxane synthase inhibitor… vs Aspirin alone vs TxSl alone vs combination
Design
Other
Authors
Loading...
Does not support clinical use; leaves open whether enhanced inhibition improves patient outcomes.
Does the combination of aspirin and a thromboxane synthase inhibitor improve the inhibition of thromboxane synthesis in vivo compared to either drug alone in healthy volunteers?
Absolute Event Rate: 98% vs 94%
p-value: p=<0.05
Pharmacologic inhibition of serum TxB2 must be virtually complete before thromboxane-dependent platelet activation is meaningfully influenced in vivo.
Reilly et al. (1987) studied Healthy volunteers (n=18). Aspirin and TxSl (UK-38, 485) vs. Aspirin alone or TxSl alone was evaluated on Inhibition of thromboxane generation ex vivo (serum TxB2) (p=<0.05). Combination of aspirin and a thromboxane synthase inhibitor in healthy volunteers increased ex vivo thromboxane inhibition (98% vs 94%; P<0.05) and in vivo synthesis inhibition (58%; P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: